ライフサイエンスコーパス: UTI

1 UTIs are amongst the most frequent bacterial infections.

2 UTIs were 4.1% (6/145) in the placebo group and 3.4% (5/

3 From January 1, 2008 to December 31, 2017, UTIs from outpatient settings (office, emergency, and vi

4 From 1 January 2008 to 31 December 2017, UTIs from outpatient settings (office, emergency, and vi

5 eated for infection (12,445 pneumonia; 9,380 UTI), nearly half (49.1%) had antibiotic overuse after d

6 d ratio [LR-] = 0.4) and rule in (LR+ = 2.6) UTI.

7 ruse after discharge (56.9% pneumonia; 38.7% UTI).

8 a foundation for investigating RNase 7 as a UTI prognostic marker or nonantibiotic-based therapy.

9 During a UTI, urease-negative E. coli bacteria thrive, despite th

10 g a protective role for neutrophils during a UTI, whereas monocyte-derived macrophages orchestrate a

11 mortality risk for sepsis vs 1.62-fold for a UTI).

12 ntrations in 29 girls and adolescents with a UTI history and 29 healthy female human controls.

13 red with controls, study participants with a UTI history had 1.5-fold lower urinary RNase 7 concentra

14 outpatient care settings to ensure accurate UTI diagnosis and reduce inappropriate antibiotic treatm

15 n to invade the urothelial wall during acute UTI, forming latent intracellular reservoirs that can ev

16 UK interpretation criteria tailored to acute UTI, failed to detect a variety of bacterial species, in

17 utants display persistent inflammation after UTI, and Nf-KB, which is transiently activated in respon

18 and the role of CD14 in host defense against UTI in the bladder.

19 ntation of the Cu-based host defense against UTI represents a novel approach to limiting bacterial co

20 se to UTI and its role in protection against UTI remain unresolved.

21 The pathogenesis of S. agalactiae UTI is complex, multifactorial, and influenced by virule

22 nfection (aOR, 2.09 [95% CI, 1.78-2.46]) and UTI (aOR, 1.93 [95% CI, 1.74-2.15]) and remained high in

23 risk factor for Escherichia bacteriuria and UTI and a 1% relative gut abundance of Enterococcus is a

24 hereas that of intra-abdominal infection and UTI increased.

25 ngs to a murine model of catheter-associated UTI (CAUTI), delineated the contribution of enhanced ure

26 ith a chronic indwelling catheter-associated UTI and sepsis hospitalized in medical departments.

27 reduce catheter use and catheter-associated UTI rates in non-ICUs.

28 icated and complicated), catheter-associated UTI, and asymptomatic bacteriuria in both women and men.

29 al E. coli strains, the relationship between UTI and ASB is poorly defined, confounding our understan

30 of antibiotic therapy for ASB, cystitis, CA-UTI and pyelonephritis were 10.0 (4.5), 11.4 (4.7), 12.0

31 has potential for use in rapid point-of-care UTI screening.

32 ethra to the urinary tract, where they cause UTIs.

33 ellular targets for the treatment of chronic UTI.

34 microparticles to effectively treat chronic UTIs.

35 Clinical UTI with pyuria was also significantly reduced (incidenc

36 xpression of Cu efflux genes during clinical UTI in patients as an adaptive response to host-derived

37 urinary Cu content observed during clinical UTI.

38 was defined as the total number of clinical UTI events (including multiple events per subject when a

39 The primary outcome was the clinical UTI incidence density, which was defined as the total nu

40 o imprint the rod-shape structure of E. coli UTI 89 into ultra-thin inorganic silica coatings on gold

41 re professionals correctly diagnosed E. coli UTI and negative urine cultures, which would help preven

42 w that, in mice, an initial Escherichia coli UTI, whether chronic or self-limiting, leaves a long-las

43 sons at risk of recurrent and/or complicated UTI.

44 o meropenem for the treatment of complicated UTIs and acute pyelonephritis caused by Enterobacteriace

45 to meropenem in the treatment of complicated UTIs, including acute pyelonephritis, with a noninferior

46 ign, uncomplicated infections to complicated UTIs (cUTIs), pyelonephritis and severe urosepsis.

47 idney transplant recipients with complicated UTIs underwent both PET with a specific CXCR4 ligand, (6

48 ed by Point-of-Care tests (PoCT) to diagnose UTI in this setting.

49 fy features that do (and do not) distinguish UTI- from ASB-associated E. coli strains.

50 tic determinants that rigorously distinguish UTI- and ASB-associated strains.

51 CRP and PCT are not suitable to distinguish UTI and ASB in nursing home residents.Trial registration

52 Dividing UTIs into three categories; febrile upper UTI (acute pye

53 ch to limiting bacterial colonization during UTI.

54 as the molecular source of urinary Cu during UTI.

55 inary copper (Cu) content is elevated during UTI caused by uropathogenic Escherichia coli (UPEC).

56 tanding of host-pathogen interactions during UTI pathogenesis.

57 reveal that Cu is mobilized to urine during UTI caused by the major uropathogens Proteus mirabilis a

58 is a host effector mobilized to urine during UTI to limit bacterial growth.

59 lamine as a potential nutrient source during UTIs is understudied.

60 ould be developed to better inform empirical UTI therapy selection in the ED.

61 thogens, and may be unsuitable for excluding UTI in patients with LUTS.

62 Experimental UTI with UPEC in nonhuman primates recapitulates the inc

63 nsgenic mice, subjected them to experimental UTI, and enumerated UPEC burden in the urine, bladder, a

64 No febrile UTI were recorded in the WOCA group vs. 9 (45.0%) (p<0.0

65 A single episode of febrile UTI is often caused by a virulent Escherichia coli strai

66 f atypical and recurrent episodes of febrile UTI should focus on urinary tract abnormalities, whereas

67 No febrile UTIs were recorded in the WOCA group versus 9 (45.0%) (P

68 Delay in treatment of febrile UTIs and permanent renal scarring are associated.

69 Secondary outcomes: number of febrile UTIs, number of hospitalisations, WOCA tolerance, antibi

70 Secondary outcomes were number of febrile UTIs, number of hospitalizations, WOCA tolerance, antibi

71 However, significantly fewer UTIs caused by E coli of any serotype were noted in the

72 of E. coli to reside in the vagina following UTI.

73 men and 784 (602-1,051) in women; following UTI, the NNT was 121 (102-145) in men and 284 (241-342)

74 ons with more advanced frailty, or following UTIs.

75 r discharge were due to excess duration; for UTI, 43.9% were due to treatment of asymptomatic bacteri

76 the use, effectiveness and safety of FT for UTI in KTRs.

77 , the probability of sepsis was greatest for UTI, followed by skin infection, followed by RTI.

78 cal diagnostic criterion (>10(5) CFU/mL) for UTI.

79 cal and urinary immunological predictors for UTI diagnosis.

80 mpirically prescribed antibiotic regimen for UTI.

81 e to traditional oral antibiotic regimes for UTI.

82 have the potential to shift the strategy for UTI treatment away from broad-spectrum antibiotics targe

83 be used to develop a point of care test for UTI but require further validation.

84 onists represent new antivirulence drugs for UTIs.

85 to 240 CFU/mL, comensurate with cut-off for UTIs (10(3)-10(5) CFUs/mL) was achieved.

86 nesses in our current treatment paradigm for UTIs.

87 nce genotype of UPEC strains responsible for UTIs is yet to be defined, due to the large variation of

88 in urogenital anatomy confer protection from UTI in males; however, as clinically observed, male sex

89 Future UTI-preventive probiotic strains may benefit by retainin

90 Outcomes studied included reflux grade, UTIs during the study on placebo or antibiotics, bowel a

91 ibiotic stewardship interventions to improve UTI treatment.

92 gA, and capsule to study the role of CovR in UTI.

93 lactiae global virulence regulator, CovR, in UTI pathogenesis is unknown.

94 ith SSI but was associated with increases in UTI after orthopedic and vascular procedures; this risk

95 ng ferroxidase, is found at higher levels in UTI urine than in healthy control urine and serves as th

96 l treatment among residents with an incident UTI (first during the study with none in the year prior)

97 identified 21,938 residents with an incident UTI treated in 120 VA CLCs, of which 96.0% were male.

98 improving in CLC residents with an incident UTI.

99 75/90 subjects) and urinary tract infection (UTI) (3/90).

100 multidrug-resistant urinary tract infection (UTI) and bloodstream infection worldwide.

101 ed for pneumonia or urinary tract infection (UTI) and determine whether overuse varied across hospita

102 ng clinical E. coli urinary tract infection (UTI) and experimental human colonization with a commensa

103 th an ICD 9/10 code urinary tract infection (UTI) diagnosis during July 2015 to June 2016 were random

104 l to UA to rule out urinary tract infection (UTI) in children.

105 UA for diagnosis of urinary tract infection (UTI) in children.

106 eria known to cause urinary tract infection (UTI) in millions of patients.

107 otics for suspected urinary tract infection (UTI) in older patients.

108 Urinary tract infection (UTI) is a major global infectious disease affecting mill

109 atment of suspected urinary tract infection (UTI) is common in long-term care facilities (LTCFs).

110 icant proportion of urinary tract infection (UTI) patients experience recurrent episodes, due to deep

111 coli) isolated from urinary-tract infection (UTI) samples.

112 with uncomplicated urinary tract infection (UTI) symptoms are commonly treated with empirical antibi

113 istory of recurrent urinary tract infection (UTI) to receive a single injection of either intramuscul

114 For urinary tract infection (UTI), a history of two or more episodes is an independen

115 es were symptomatic urinary tract infection (UTI), all-cause death, all-cause hospitalization, all mu

116 or pneumonia (PNA), urinary tract infection (UTI), and acute bacterial skin and skin structure infect

117 tion (RTI), skin or urinary tract infection (UTI), and antibiotic prescriptions were exposures.

118 te infection (SSI), urinary tract infection (UTI), and lower respiratory tract infection (LRTI).

119 P as a biomarker of urinary tract infection (UTI), confirming the capability of the ATP sensing paper

120 role in preventing urinary tract infection (UTI), we quantified urinary RNase 7 concentrations in 29

121 One such area is urinary tract infection (UTI), which is one of the most common infectious disease

122 dressed its role in urinary tract infection (UTI), which remains largely unknown.

123 women experiencing urinary tract infection (UTI)-like symptoms.

124 test for confirming urinary tract infection (UTI).

125 tion in response to urinary tract infection (UTI).

126 of bacteriuria and urinary tract infection (UTI).

127 minal infection, or urinary tract infection (UTI).

128 galactiae can cause urinary tract infection (UTI).

129 erity in a model of urinary tract infection (UTI).

130 not been studied in urinary tract infection (UTI).

131 ins associated with urinary tract infection (UTI).

132 mon infections were urinary tract infection (UTI; 46.8%) and pneumonia (28.2%).

133 Urinary tract infection (UTIs) was higher in CC group (40%) compared to CPI group

134 Urinary tract infections (UTI) are one of the most common bacterial infections and

135 Diagnosing urinary tract infections (UTI) in nursing home residents is complex, as specific u

136 e primary cause of urinary tract infections (UTIs) - can adhere to vaginal epithelial cells preceding

137 ical isolates from urinary tract infections (UTIs) after 15 min of exposure for all four antibiotic c

138 such as recurrent urinary tract infections (UTIs) and interstitial cystitis have been studied utiliz

139 Urinary tract infections (UTIs) are a microbial disease reported worldwide.

140 Urinary tract infections (UTIs) are among the most commonly treated bacterial infe

141 Urinary tract infections (UTIs) are common and in general are caused by intestinal

142 Urinary tract infections (UTIs) are common in both inpatient and outpatient settin

143 Urinary tract infections (UTIs) are common, recurrent infections that can be mild

144 Complicated urinary tract infections (UTIs) are frequent in immunosuppressed patients after ki

145 Urinary tract infections (UTIs) are one of the most common bacterial infections in

146 Urinary tract infections (UTIs) are the most commonly reported infections in adult

147 Urinary tract infections (UTIs) caused by Escherichia coli create a large burden o

148 Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) af

149 ultidrug-resistant urinary tract infections (UTIs) disrupt the gut microbiome and promote antibiotic

150 Urinary tract infections (UTIs) in children are among the most common bacterial in

151 The treatment of urinary tract infections (UTIs) in kidney transplant recipients (KTRs) with oral a

152 Urinary tract infections (UTIs) occur commonly, but recent data on UTI rates are s

153 Urinary tract infections (UTIs) represent a major burden across the population, al

154 Urinary tract infections (UTIs) typically evoke prompt and vigorous innate bladder

155 ng risk for severe urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhib

156 fragmentation, and urinary tract infections (UTIs) within 3 mo of transplantation.

157 s with complicated urinary tract infections (UTIs), including acute pyelonephritis, in a 1:1 ratio to

158 is associated with urinary tract infections (UTIs), one of the most common infectious diseases in the

159 at can result from urinary tract infections (UTIs), which commonly ascend from the bladder to the kid

160 py for symptomatic urinary tract infections (UTIs), yet large-scale evaluations of bacteriuria manage

161 t of uncomplicated urinary tract infections (UTIs).

162 tness advantage in urinary tract infections (UTIs).

163 outcomes (such as urinary tract infections [UTIs] managed in the community or in outpatients) could

164 c parental strain, TX82, in a mixed-inoculum UTI model (P < 0.001 to 0.048), that reconstitution of e

165 in 40 KTRs were included (ASB, n = 15; lower UTI, n = 33; upper UTI, n = 5).

166 ds to be broad and last for 10 days, a lower UTI only needs to be treated for 3 days, often with a na

167 allograft infection in 9 patients and lower UTI/nonurologic infections in the remaining 4 patients.

168 cal cure in 25%, 28%, and 100% of ASB, lower UTI and upper UTI with initial positive culture and foll

169 Clinical cure rates were 67% for lower UTI and 80% for upper UTI.

170 ation between antibiotic treatment for lower UTI and risk of bloodstream infection (BSI) in adults ag

171 ness as last-resort oral treatment for lower UTI and stepdown treatment for upper UTI in KTRs.

172 eated with FT as initial treatment for lower UTI or asymptomatic bacteriuria (ASB) or as stepdown tre

173 gnostic marker to distinguish APN from lower UTI and function as a diagnostic marker indicative of VU

174 ESR and DNI were higher in APN than in lower UTI (p < 0.01).

175 luded representing 280,462 episodes of lower UTI.

176 rile upper UTI (acute pyelonephritis), lower UTI (cystitis), and asymptomatic bacteriuria, is useful

177 e recently to carbapenems and colistin, make UTI a prime example of the antibiotic-resistance crisis

178 Our results support a gut microbiota-UTI axis, suggesting that modulating the gut microbiota

179 physiological changes, like frequency, mimic UTI symptoms, and therefore bacteriological cultures are

180 Modelling UTIs in vitro, human vaginal and bladder epithelial cell

181 eases an individual's susceptibility to MRSA UTI.

182 ermanente Southern California using multiple UTI definitions.

183 ermanente Southern California using multiple UTI definitions.

184 lium is detected in acute and chronic murine UTI models indicating the ability of E. coli to reside i

185 med to occur 1-hour post experimental murine UTI in ICs but not in non-ICs.

186 particularly helpful in ruling out negative UTI cases.

187 unosensor was tested using other UTI and non-UTI bacteria, Staphylococcus, Klebsiella, Proteus and Sh

188 After excluding patients with non-UTI indications for antibiotics, 72% of patients with AS

189 ical practice, risk for severe and nonsevere UTI events among those initiating SGLT-2 inhibitor thera

190 BSI occurred in 0.4% (1,025/244,963) of UTI episodes with immediate antibiotics versus 0.6% (228

191 diness (turbidity) increased the accuracy of UTI prediction further (LR+ = 4.4).

192 technical obstacles, preclinical modeling of UTI in male mice has been limited.

193 d human bladder uroepithelial cell models of UTI and S. agalactiae mutants in covR and related factor

194 monstrated oral activity in animal models of UTI but were found to have limited compound exposure due

195 particles were effective against a number of UTI-relevant bacterial strains.

196 However, the clinical phenotypes of UTI are heterogeneous and range from rather benign, unco

197 mproved antibiotic susceptibility profile of UTI-causing organisms.

198 tions that are responsible for around 80% of UTIs, helping to stop the over-prescription of antibioti

199 erial species is the most prevalent agent of UTIs worldwide and can also colonize the urogenital trac

200 In post-hoc exploratory analyses of UTIs with higher bacterial counts (>/=10(5) colony-formi

201 st for the description and classification of UTIs, with the common rationale that cUTIs have a higher

202 majority of stent complications consisted of UTIs, with an incidence of 31 of 126 (24.6%) in the late

203 antibody functionality, and the incidence of UTIs caused by E coli vaccine serotypes in each group.

204 No reduction in the incidence of UTIs with 10(3) or more colony-forming units per mL of v

205 The overwhelming majority of UTIs are caused by uropathogenic Escherichia coli (UPEC)

206 linically relevant overview of management of UTIs, including screening, diagnosis, treatment, and pre

207 roducts have been used for the prevention of UTIs with varying degrees of success.

208 mannosides could markedly reduce the rate of UTIs and recurrent UTIs.

209 the extraordinarily high recurrence rates of UTIs, we examined adaptive immune responses in mouse bla

210 Thus, recurrence of UTIs and associated bladder dysfunction are the outcome

211 ns (UTIs) occur commonly, but recent data on UTI rates are scarce.

212 d >=65 years in England with community-onset UTI using the Clinical Practice Research Datalink (2007-

213 spitalized patients treated for pneumonia or UTI in 46 hospitals between 7/1/2017-7/30/2019 we quanti

214 of this immunosensor was tested using other UTI and non-UTI bacteria, Staphylococcus, Klebsiella, Pr

215 Outpatient UTI rates increased from 2008 to 2017, especially in vir

216 tual health care delivery affects outpatient UTI management and trends in the United States.

217 rtual healthcare delivery affects outpatient UTI management and trends in the United States.

218 hritis; the secondary outcome was outpatient UTI treated with antibiotics.

219 ssociated with increased risk for outpatient UTIs (cohort 1: HR, 0.96 [CI, 0.89 to 1.04]; cohort 2: H

220 ommon factor in the management of outpatient UTIs.

221 Overall, UTI rates were highest and increased the most in older a

222 ter courses of antibiotic treatment for PNA, UTI, and ABSSSI with bacteremia were not associated with

223 study of inpatients with uncomplicated PNA, UTI, or ABSSSI and associated bacteremia.

224 adhere to vaginal epithelial cells preceding UTI.

225 may be a potential novel strategy to prevent UTIs.

226 nt, defined as a hospitalization for primary UTI, sepsis with UTI, or pyelonephritis; the secondary o

227 Age, menopausal status, prior UTI, and host genetics were top factors defining the uro

228 The prevalence of culture-proven UTI among pregnant women with UTI symptoms was 4%.

229 efficient and well-tolerated in preventing R-UTI in SCI patients.

230 stration of two antibiotics, in preventing R-UTI.

231 t self-catheterization, and suffering from R-UTIs.

232 t self-catheterization, and suffering from R-UTIs.

233 Recurrent urinary tract infections (R-UTIs) are the main cause of morbidity and hospitalisatio

234 Recurrent urinary tract infections (R-UTIs) are the main cause of morbidity and hospitalizatio

235 efficient and well tolerated in preventing R-UTIs in SCI patients.

236 nistration of 2 antibiotics) in preventing R-UTIs.

237 Recurrent UTI (RUTI) greatly reduces quality of life, places a sig

238 difficile, significantly decreased recurrent UTI frequency, and improved antibiotic susceptibility pr

239 he development of therapeutics for recurrent UTI.

240 mples from women with a history of recurrent UTI.

241 rkedly reduce the rate of UTIs and recurrent UTIs.

242 apy, 30-50% of patients experience recurrent UTIs.

243 t of these in patients with catheter related UTI (CaUTI).

244 nits per mL), the number of vaccine serotype UTIs did not differ significantly between groups (0.046

245 ly receiving SGLT-2 inhibitors had 61 severe UTI events (incidence rate [IR] per 1000 person-years, 1

246 The primary outcome was a severe UTI event, defined as a hospitalization for primary UTI,

247 served, male sex associated with more severe UTI once these traditional anatomic barriers were bypass

248 ucidate the molecular determinants of severe UTI and have implications for the early detection of thi

249 , defined as isolates associated with severe UTI, i.e., kidney infection (pyelonephritis) or urinary-

250 n total, 49 episodes fulfilled our stringent UTI definition (19.8%).

251 The original sample size was 440 suspected UTI episodes, to detect a clinically relevant sensitivit

252 residents (>= 65 years old) with a suspected UTI were recruited from psychogeriatric, somatic, or reh

253 rical antibiotic prescriptions for suspected UTI at an urgent care clinic among patients >=70 years o

254 o guide antibiotic prescribing for suspected UTI in older adults.

255 isms, antibiotics administered for suspected UTI, and total antimicrobial administration.

256 g antibiotics in older adults with suspected UTI did not increase patients' risk of BSI, in contrast

257 les from urgent care patients with suspected UTI, 306 (41%) yielded E. coli, from 35 different clonal

258 ences occurred in 31% and 24% of symptomatic UTI episodes, without severe clinical failure.

259 durations of therapy for ASB and symptomatic UTIs.

260 BL-PE are more often associated with TD than UTI.

261 ding on the patient population analysed, the UTI entities included and the primary outcome of the stu

262 nstitution of empA restored virulence in the UTI model, and that deletion of empA also resulted in at

263 In the UTI model, mice coinfected with the two species exhibite

264 those who were treated on the date of their UTI consultation (adjusted odds ratio [aOR] 1.13, 95% CI

265 is mobilized to urine as a host response to UTI and its role in protection against UTI remain unreso

266 se given CPIs, particularly when it comes to UTIs.

267 for all four antibiotic classes relevant to UTIs.

268 ost-operative surgical (SSI), urinary tract (UTI), and C. difficile infections.

269 perative surgical site (SSI), urinary tract (UTI), and Clostridioides difficile infections.

270 incidence of symptomatic antibiotic-treated UTIs was 1.0 (0.5-2.5) in the WOCA group versus 2.5 (1.2

271 incidence of symptomatic antibiotic-treated UTIs was 1.0 [IQR 0.5; 2.5] in the WOCA group vs. 2.5 [I

272 incidence of symptomatic antibiotic-treated UTIs.

273 incidence of symptomatic antibiotic-treated UTIs.

274 biotics has proved disappointing in treating UTI, likely due to the failure of infused antibiotics to

275 UPEC isolates, while simultaneously treating UTI, without notably disrupting the structural configura

276 sitivities, a stringent definition of 'true' UTI was used including the presence of symptoms, urinary

277 all mandatory items required for the 'true' UTI definition (92.9%) were available.

278 erial culture among women with uncomplicated UTI symptoms using random forest or support vector machi

279 olated from 14 patients during uncomplicated UTIs.

280 ression or severe outcome than uncomplicated UTIs.

281 a common transcriptional program underlying UTIs and illuminates the molecular underpinnings that li

282 ng roles for CD14 in the bladder during UPEC UTI.

283 luded (ASB, n = 15; lower UTI, n = 33; upper UTI, n = 5).

284 Treatment of an upper UTI needs to be broad and last for 10 days, a lower UTI

285 %, 28%, and 100% of ASB, lower UTI and upper UTI with initial positive culture and follow-up culture

286 ng UTIs into three categories; febrile upper UTI (acute pyelonephritis), lower UTI (cystitis), and as

287 ria (ASB) or as stepdown treatment for upper UTI after initial intravenous antibiotics.

288 r lower UTI and stepdown treatment for upper UTI in KTRs.

289 tes were 67% for lower UTI and 80% for upper UTI.

290 Compared to office and emergency visits, UTIs were increasingly diagnosed in virtual visits, wher

291 Compared to office and emergency visits, UTIs were increasingly diagnosed in virtual visits, wher

292 charge in patients treated for pneumonia vs. UTI.

293 The most common infections were UTI (33.5% of ILDKT vs. 21.5% compatible), opportunistic

294 tabolic genotypes previously associated with UTI (dsdCXA, metE) were mainly limited to phylogroup B2.

295 nd 39 (41%) ExPEC/UPEC (none associated with UTI).

296 brids (2 associated with diarrhea, none with UTI).

297 hospitalization for primary UTI, sepsis with UTI, or pyelonephritis; the secondary outcome was outpat

298 culture-proven UTI among pregnant women with UTI symptoms was 4%.

299 Stratification of patients with UTIs is, therefore, important.

300 Residents with UTIs receiving potentially suboptimal treatment were com

301 riuria among pregnant women with and without UTI symptoms in Uganda.